Larry Luxner,  —

Articles by Larry Luxner

Recommendation Against U.K. Coverage of Brineura Jolts Batten Disease Community

A preliminary recommendation against British National Health Service insurance coverage of the $702,000-a-year therapy Brineura (cerliponase alfa) to treat a specific type of Batten disease is “cruel and inaccurately based,” the U.K. nonprofit Batten Disease Family Association contends. The expensive drug, manufactured by San Francisco-based BioMarin, is aimed…

Batten Organization’s Director Says Scientists Zeroing In on Treatments

WASHINGTON — As the Batten Disease Support and Research Association celebrates its 30th anniversary, the group’s executive director says scientists are edging ever closer to treatments for the incurable genetic disorder. Margie Frazier said the organization she’s headed for five years is the only one that represents all 14 forms…